Investor Presentation for the Quarter and Nine Months Ended on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals reported weak Q3FY26 standalone results, with revenue falling 39% YoY to ₹41.4 crore, EBITDA declining 58% to ₹3.5 crore, and PAT dropping 70% to ₹2 crore, mainly due to timing differences in institutional order execution. However, EBITDA improved 50% sequentially with margins expanding 280 basis points to 8%, reflecting better cost discipline. On a consolidated basis, revenue stood at ₹65.2 crore (down 10% YoY) with a net loss of ₹9.6 crore, as subsidiary Innoxel and Varenyam Bio are still in heavy investment phases. Key regulatory wins include USFDA approval for the Baroda facility and a clean EU GMP inspection with zero critical observations. The company has a ₹303 crore order book expected to spill into FY27, and management is confident of strong recovery next year.
Near-term pain as the company will miss its full-year FY26 revenue guidance, but the strong order pipeline, regulatory clearances, and management's confidence in FY27 suggest a recovery story. Shareholders should watch for execution of the ₹303 crore order book and Innoxel's path to PAT profitability in FY27 as key catalysts.